Mitochondrial DNA copy number is associated with mortality and infections in a large cohort of patients with chronic kidney disease.


Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
08 2019
Historique:
received: 12 12 2018
revised: 29 03 2019
accepted: 05 04 2019
pubmed: 30 6 2019
medline: 2 10 2020
entrez: 29 6 2019
Statut: ppublish

Résumé

Damage of mitochondrial DNA (mtDNA) with reduction in copy number has been proposed as a biomarker for mitochondrial dysfunction and oxidative stress. Chronic kidney disease (CKD) is associated with increased mortality and risk of cardiovascular disease, but the underlying mechanisms remain incompletely understood. Here we investigated the prognostic role of mtDNA copy number for cause-specific mortality in 4812 patients from the German Chronic Kidney Disease study, an ongoing prospective observational national cohort study of patients with CKD stage G3 and A1-3 or G1-2 with overt proteinuria (A3) at enrollment. MtDNA was quantified in whole blood using a plasmid-normalized PCR-based assay. At baseline, 1235 patients had prevalent cardiovascular disease. These patients had a significantly lower mtDNA copy number than patients without cardiovascular disease (fully-adjusted model: odds ratio 1.03, 95% confidence interval [CI] 1.01-1.05 per 10 mtDNA copies decrease). After four years of follow-up, we observed a significant inverse association between mtDNA copy number and all-cause mortality, adjusted for kidney function and cardiovascular disease risk factors (hazard ratio 1.37, 95% CI 1.09-1.73 for quartile 1 compared to quartiles 2-4). When grouped by causes of death, estimates pointed in the same direction for all causes but in a fully-adjusted model decreased copy numbers were significantly lower only in infection-related death (hazard ratio 1.82, 95% CI 1.08-3.08). A similar association was observed for hospitalizations due to infections in 644 patients (hazard ratio 1.19, 95% CI 1.00-1.42 in the fully-adjusted model). Thus, our data support a role of mitochondrial dysfunction in increased cardiovascular disease and mortality risks as well as susceptibility to infections in patients with CKD.

Identifiants

pubmed: 31248648
pii: S0085-2538(19)30483-1
doi: 10.1016/j.kint.2019.04.021
pii:
doi:

Substances chimiques

DNA, Mitochondrial 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

480-488

Investigateurs

Kai-Uwe Eckardt (KU)
Heike Meiselbach (H)
Markus Schneider (M)
Thomas Dienemann (T)
Hans-Ulrich Prokosch (HU)
Barbara Bärthlein (B)
Andreas Beck (A)
Thomas Ganslandt (T)
André Reis (A)
Arif B Ekici (AB)
Susanne Avendaño (S)
Dinah Becker-Grosspitsch (D)
Ulrike Alberth-Schmidt (U)
Birgit Hausknecht (B)
Rita Zitzmann (R)
Anke Weigel (A)
Gerd Walz (G)
Anna Köttgen (A)
Ulla Schultheiß (U)
Fruzsina Kotsis (F)
Simone Meder (S)
Erna Mitsch (E)
Ursula Reinhard (U)
Jürgen Floege (J)
Georg Schlieper (G)
Turgay Saritas (T)
Sabine Ernst (S)
Nicole Beaujean (N)
Elke Schaeffner (E)
Seema Baid-Agrawal (S)
Kerstin Theisen (K)
Hermann Haller (H)
Jan Menne (J)
Martin Zeier (M)
Claudia Sommerer (C)
Rebecca Woitke (R)
Gunter Wolf (G)
Martin Busch (M)
Rainer Fuß (R)
Thomas Sitter (T)
Claudia Blank (C)
Christoph Wanner (C)
Vera Krane (V)
Antje Börner-Klein (A)
Britta Bauer (B)
Florian Kronenberg (F)
Julia Raschenberger (J)
Barbara Kollerits (B)
Lukas Forer (L)
Sebastian Schönherr (S)
Hansi Weissensteiner (H)
Peter Oefner (P)
Wolfram Gronwald (W)
Helena Zacharias (H)
Matthias Schmid (M)
Jennifer Nadal (J)

Informations de copyright

Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Auteurs

Federica Fazzini (F)

Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.

Claudia Lamina (C)

Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.

Liane Fendt (L)

Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.

Ulla T Schultheiss (UT)

Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany; Renal Division, Department of Medicine IV, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany.

Fruzsina Kotsis (F)

Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.

Andrew A Hicks (AA)

Institute for Biomedicine, EURAC Research, Affiliated Institute of the University of Lübeck, Bolzano, Italy.

Heike Meiselbach (H)

Department of Nephrology and Hypertension, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.

Hansi Weissensteiner (H)

Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.

Lukas Forer (L)

Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.

Vera Krane (V)

Division of Nephrology, Department of Internal Medicine I, Division of Nephrology and Comprehensive Heart Failure Centre, University Hospital Würzburg, Würzburg, Germany.

Kai-Uwe Eckardt (KU)

Department of Nephrology and Hypertension, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Anna Köttgen (A)

Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.

Florian Kronenberg (F)

Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: Florian.Kronenberg@i-med.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH